Table 6 Cost parameters: medication and adverse events
Cost (€) | Share of patients | Sources | |
|---|---|---|---|
Dabrafenib/trametinib, annual costs, including application | 114,411 € | Source: manufacturer dossier [81], price adjustment 2019/2020 | |
Nivolumab, annual costs, including application | 78,460 € | Source: manufacturer dossier [82] | |
Adverse events | € per patient | ||
AE degree 1–2, dabrafenib/trametinib | 227.37 € | 55.6% | |
AE degree 3–4, dabrafenib/trametinib | 113.26 € | 41.4% | |
AE degree 1–2, observation | 96.45 € | 73.8% | |
AE degree 3–4, observation | 14.86 € | 14.1% | |
AE degree 1–2, nivolumab | 231.92 € | 71.3% | |
AE degree 3–4, nivolumab | 179.42 € | 25.4% |